Table 2. Clinical and research immune studies laboratory data.
| All Patients | Activated T-cell hepatitis | Indeterminate PALF | P value | |
|---|---|---|---|---|
| n = 8 | n = 4 | n = 4 | ||
| Soluble IL-2 receptor (IU/mL) | 2116 (1689–6433) | 4588 (1689–8653) | 2116 (1875–3135) | 0.70 |
| Perforin and Granzyme B Assay, n | 6 | 4 | 2 | |
| % CD8 T-cells Perforin+ | 23.5 (12.5–33.0) | 29.5 (18.5–44.0) | 16.5 (12.8–20.3) | 0.80 |
| % CD8 T-cells Granzyme+ | 43.5 (21.5–63.3) | 60.5 (44.5–70.0) | 25.0 (21.5–28.5) | 0.53 |
| Clinical T & B cell quantitation | ||||
| CD4 to CD8 T-cell ratio | 1.4 (0.3–1.8) | 0.3 (0.3–0.7) | 1.8 (1.5–2.6) | 0.11 |
| % CD8+ T-cells | 28.0 (23.5–34.8) | 34.5 (26.5–40.3) | 26.0 (21.3–28.5) | 0.34 |
| % HLA-DR+ T-cells | 12.0 (5.0–31.0) | 32.0 (23.8–37.3) | 8.0 (4.8–11.5) | 0.14 |
| Research Flow cytometry | ||||
| CD4 to CD8 T-cell ratio | 1.6 (1.0–2.1) | 0.8 (0.3–1.6) | 1.8 (1.7–3.3) | 0.20 |
| % CD8+ T-cells | 34.5 (29.3–42.2) | 46.3 (34.7–56.2) | 32.4 (26.1–34.1) | 0.20 |
| % Effector memory CD8+ T-cells | 29.5 (21.6–66.6) | 66.8 (57.4–68.7) | 19.1 (13.4–25.2) | 0.03 |
| % Effector memory CD8+ CD103+ T-cells | 7.1 (4.7–11.3) | 12.4 (9.5–14.7) | 4.7 (4.5–5.3) | 0.03 |
aData are medians (interquartile range).